SciFluor raises $30M in series A
Allied Minds plc (LSE:ALM) subsidiary SciFluor Life Sciences LLC (Cambridge, Mass.) raised $30 million in an untranched series A round led by new investors Invesco Asset Management and Woodford Investment Management. Allied Minds and affiliated investors also participated.
SciFluor plans to start up to four clinical trials in 1Q16 evaluating lead candidates SF0166 and SF0034 in two indications each. SF0166 is a fluorinated small molecule integrin antagonist to treat wet age-related macular degeneration (AMD) and diabetic macular edema (DME). SF0034, a potassium channel Kv7.2 ( KCNQ2) and KCNQ3 modulator and fluorinated derivative of ezogabin, is in development to treat neurological diseases including epilepsy and pediatric encephalopathy. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) markets ezogabin as Potiga in the U.S. and Trobalt in the EU to treat epilepsy. ...